Haleon plc
GBFinancials
Valuation Metrics
Haleon plc's Market Cap is $38.87B. At end of 2025 it was $42.32B. Ranked #387 of 3,116 in US market (top 12%), #277 of 1,644 on NYSE (top 17%), #23 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 9%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $38.87B | US#387/3,116 Sec#23/265 |
| Total Assets | $43.61B | US#361/3,116 Sec#15/265 |
| Net Assets | $21.93B | US#221/3,116 Sec#13/265 |
| Employees | 24,535 | US#461/3,116 Sec#18/265 |
| Value | ||
| P/B | 1.77x | US#1,062/3,116 Sec#45/265 |
| P/S | 2.67x | US#1,523/3,116 Sec#41/265 |
| Financial Health | ||
| Debt Ratio | 98.54% | US#1,078/3,116 Sec#161/265 |
| Total Debt | $11.05B | US#384/3,116 Sec#18/265 |
| Cash | $1.11B | US#625/3,116 Sec#29/265 |
| Current Ratio | 0.69x | US#2,601/3,116 Sec#264/265 |
| Dividend | ||
| Div. Yield | 2.03% | US#911/3,116 Sec#16/265 |
| Div. Growth | 5.02% | US#809/3,116 Sec#10/265 |
| Performance | ||
| 1Y Return | -5.34% | US#2,012/3,116 Sec#163/265 |
| 1M Return | -0.28% | US#2,341/3,116 Sec#170/265 |
| From 52W High | -22.21% | US#1,746/3,116 Sec#106/265 |
| 1Y MDD | -23.96% | US#911/3,116 Sec#35/265 |
| Trading | ||
| Volume | 32,961,720 shares | US#14/3,116 Sec#2/265 |
| Trading Value | $288M | US#235/3,116 Sec#13/265 |
| Per Share | ||
| BPS | $4.95 | US#2,278/3,116 Sec#129/265 |
Company Info
Haleon plc is a significant global entity in the consumer healthcare sector, engaging in the entire process from scientific research and development to the production and worldwide distribution of various wellness goods. The company's reach extends across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific region. Its diverse product portfolio encompasses therapeutic solutions for oral care, pain management, respiratory well-being, and digestive health, alongside a comprehensive range of vitamins, minerals, and other dietary supplements. Noteworthy brands within its collection include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially known as DRVW 2022 plc before officially changing its name to Haleon plc in February 2022. It is headquartered in Brentford, United Kingdom.